ORMELOXIFENE: UNRAVELING DURATION OF USE AND CONTINUATION TRENDS IN CONTRACEPTIVE SEEKERS

Background: India's population growth demands effective contraception methods to reduce maternal and neonatal mortality. Limited access to contraceptives underscores the need for practical solutions. Ormeloxifene, a non-steroidal contraceptive, offers a unique approach without hormonal disruption. This study evaluates Ormeloxifene's use, focusing on continuation rates and reasons for discontinuation in diverse demographic groups. Methods: The study included 177 women aged 18-35, divided into postpartum, postabortal, and interval contraception groups. Ormeloxifene initiation details and follow-up visits were documented. Demographic, menstrual, obstetric, and medical data were collected, ensuring condentiality. Participants were evaluated for menstrual complaints, side effects, and willingness to continue. Results: Ormeloxifene demonstrated a high continuation rate (98.8% at 3 months and 94.4% at 6 months). Menstrual complaints, primarily delayed menses, were common side effects. Religion and socioeconomic status inuenced contraceptive practices. Ormeloxifene's safety and acceptability were comparable across different initiation periods. Conclusion: Ormeloxifene proved to be an acceptable and safe contraceptive option for women in postpartum, postabortal, and interval periods. Despite minor menstrual complaints, it had a high continuation rate, indicating its potential as an effective contraceptive method in diverse populations. Adequate counseling and information dissemination are crucial for managing expected side effects and ensuring user satisfaction.